Stemson Appoints Meghan Samberg, PhD, as Vice President, R&D and Preclinical Development
Stemson Therapeutics is pleased to announce Meghan Samberg, PhD, joined our team as Vice President, R&D and Preclinical Development. Dr. Samberg will lead Stemson’s research and development efforts to prepare for human clinical trials of our hair growth cell therapy and will be responsible for helping drive regulatory and clinical strategy.
“Meghan brings extensive preclinical and clinical research experience and adds depth to the Stemson management team. Her expertise in tissue engineering strategies, particularly in skin applications, combined with her background developing regulatory approved products complements our existing expertise in stem cell biology and cell therapy,” said Geoff Hamilton, Chief Executive Officer of Stemson Therapeutics.
“I am excited to join Stemson and support their audacious approach to hair regeneration. I am eager to apply my capabilities of developing skin tissue engineering constructs and preclinical programs to diligently progress the company toward clinical trial. I look forward to working with the impressive team of exceptionally motivated and entrepreneurial scientists and business leaders,” said Dr. Samberg.
Dr. Samberg is experienced in growing seed stage companies within the fields of regenerative and translational medicine with specialties in skin wound healing, tissue engineering, animal model development and testing, nanoparticle toxicology, biomaterial fabrication, and lyophilization. Prior to joining Stemson, Meghan simultaneously served as the VP of Clinical Affairs at ISTO Biologics, an orthobiologics company, where she led all laboratory, preclinical, and clinical research efforts, and VP & GM of Compass Biomedical, a small biologics company specializing in blood-based products and therapies where she was responsible for overall strategy, managing daily operations, and financial performance. In addition to serving as the PI and PM on multi-million-dollar NIH, DoD, and BARDA funded preclinical and clinical programs for Compass products, she oversaw the CDMO services for seed stage companies, translating their R&D concepts into cGMP processes and serving as their regulatory contact. She is particularly adept at understanding the motivators of different people and engaging different management strategies to optimize performance.
Meghan holds a BS in Biological Engineering from the University of Georgia, an MS in Biomedical Engineering from Yale University, and a PhD from The University of North Carolina at Chapel Hill and North Carolina State University. She conducted post-doctoral research at NCSU and at the United States Army Institute for Surgical Research at Fort Sam Houston.